Department of Chemistry, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.
Nucleic Acids Res. 2021 Apr 6;49(6):e32. doi: 10.1093/nar/gkaa1231.
Various in vivo mutagenesis methods have been developed to facilitate fast and efficient continuous evolution of proteins in cells. However, they either modify the DNA region that does not match the target gene, or suffer from low mutation rates. Here, we report a mutator, eMutaT7 (enhanced MutaT7), with very fast in vivo mutation rate and high gene-specificity in Escherichia coli. eMutaT7, a cytidine deaminase fused to an orthogonal RNA polymerase, can introduce up to ∼4 mutations per 1 kb per day, rivalling the rate in typical in vitro mutagenesis for directed evolution of proteins, and promotes rapid continuous evolution of model proteins for antibiotic resistance and allosteric activation. eMutaT7 provides a very simple and tunable method for continuous directed evolution of proteins, and suggests that the fusion of new DNA-modifying enzymes to the orthogonal RNA polymerase is a promising strategy to explore the expanded sequence space without compromising gene specificity.
已经开发了各种体内诱变方法,以促进蛋白质在细胞内的快速高效连续进化。然而,它们要么修饰与靶基因不匹配的 DNA 区域,要么突变率低。在这里,我们报告了一种在大肠杆菌中具有非常快的体内突变率和高基因特异性的诱变剂 eMutaT7(增强型 MutaT7)。eMutaT7 是一种与正交 RNA 聚合酶融合的胞嘧啶脱氨酶,每天每 1 kb 可引入多达 ∼4 个突变,与典型的体外蛋白质定向进化中的突变率相媲美,并促进抗生素抗性和变构激活等模型蛋白的快速连续进化。eMutaT7 为蛋白质的连续定向进化提供了一种非常简单和可调的方法,并表明将新的 DNA 修饰酶与正交 RNA 聚合酶融合是一种很有前途的策略,可以在不影响基因特异性的情况下探索扩展的序列空间。